Dr. Reddy’s Announces the Approval of Azacitidine for Injection
Dr. Reddy’s Laboratories announced today that Azacitidine for Injection 100 mg/vial, a bioequivalent generic version of VIDAZA ® (azacitidine for injection), is approved by the United States Food & Drug Administration (USFDA) on September 16, 2013. The launch of product in the market is planned in the near-term.
The VIDAZA ® brand had U.S. sales of approximately $378.5 Million for the most recent twelve months ending July 2013 according to IMS Health.
Dr. Reddy’s Azacitidine for Injection 100 mg/vial is available in single-use vials.